is noteworthy due to its association with poor clinical outcomes including therapeutic failure and cancer recurrence. 2, 3, 5 Apart from chemoresistance, cisplatin therapy is beset with marked adverse effects that hamper its clinical use. A rapid decline in kidney function (acute kidney injury) is a limiting factor in cisplatin chemotherapy and often results in treatment discontinuation. [6] [7] [8] Up to 34% of cancer patients treated with cisplatin exhibited various degrees of nephrotoxicity. [9] [10] [11] Hence, elucidation of the pathogenesis of cisplatin-induced acute kidney injury (AKI) is essential for the development of adjunctive therapies to reduce morbidity and mortality in cancer patients.
The Notch signaling, a highly conserved cellular pathway controls cell fate specification, survival and differentiation. 12, 13 The interaction between Notch ligands (Jagged1 and 2; Delta-like1, 3 and 4) and their transmembrane receptors (Notch1-4) on adjacent cells activate proteolytic cleavage of the Notch receptors by γ-secretases thereby releasing the Notch intracellular domain (NICD) into the cytoplasm. 12, 13 NICD translocates into the nucleus and forms a complex with transcriptional factors that regulate the expression of target genes. 12, 13 Dysregulation of the Notch signaling pathway has been implicated in the pathophysiology of both cancer 12, 13 and kidney disease. 14, 15 Recent reports suggest that Notch signaling is upregulated in cisplatin-resistant cancer. [16] [17] [18] [19] [20] Accordingly, targeting the Notch signaling pathway with pharmacological inhibitors of γ-secretase or knockdown of Notch components increased cisplatin efficacy against several cancer cells. 17, [21] [22] [23] [24] [25] [26] [27] Whether enhancement of the anti-cancer effect of cisplatin by Notch inhibition comes at the cost of increased kidney injury is unknown. In the present study, we investigated whether Notch signaling is induced in the kidneys of cisplatin-treated mice. We also tested the hypothesis that pharmacological inhibition of the Notch signaling pathway ameliorates cisplatin-induced AKI.
| MATERIALS AND METHODS

| Animals
All experimental animal procedures were reviewed and approved by the Animal Care and Use Committee of the University of Tennessee Health Science Center (UTHSC). Male mice (C57BL/6J; 8-10 weeks old; Jackson Laboratories, Bar Harbor, ME, USA) were used in this study.
| In Vivo studies
Cisplatin and DAPT were solubilized in pharmaceutical excipient sulfobutyl ether-β-cyclodextrin (20% Captisol) [28] [29] [30] as we have previously described. 31 Mice were randomized into four groups ( Figure 1 ; n = 16/group) and housed in ventilated micro-isolation cages. A group of mice was given a single intraperitoneal (IP) injection of cisplatin (15 mg/kg). Mice in the control groups were treated (IP) with Captisol or DAPT (15 mg/kg) alone. Another group received DAPT 1 hour before cisplatin administration, followed by daily DAPT injection for 4 days. The dose of cisplatin used was chosen based on a previous study that determined the dose-response nephrotoxic effect of cisplatin in mice upon single IP injections. 32 The injection volume was kept at 10 μL/g body weight. On the fifth day, each mouse was weighed and placed on a new 96-well plate inside an empty box for~2 hours. 31, 33 Urine samples were collected from the wells and analyzed. Blood was obtained from anesthetized mice via retro-orbital bleeding. Kidneys were collected, weighed and processed after mice had been euthanized with sodium pentobarbital (200 mg/kg; IP) followed by exsanguination.
| Determination of kidney function
To evaluate kidney function, we measured plasma or urinary concentrations of creatinine, urea nitrogen, cystatin C, neutrophil gelatinase-associated lipocalin (NGAL) and albumin. We also determined the glomerular filtration rate (GFR) in the mice. Plasma and urinary creatinine concentrations were evaluated by mass spectrometry (iso- GFR was evaluated using the FIT-GFR Inulin Kit and a one-compartment plasma clearance method (BioPhysics Assay Laboratory;
BioPAL, Worcester, MA, USA) according to the manufacturer's instructions and as previously described. [36] [37] [38] Briefly, mice were injected with GFR-grade inulin (5 mg/kg; IP). Blood samples were then collected at 30, 60 and 90 minutes post injection from the retro-orbital plexus under isoflurane anesthesia. Inulin concentrations in plasma samples were measured using the BioPAL inulin ELISA plate. The data were fit to a one-phase exponential decay equation y = Be −bX , where y is inulin concentration, B is the intercept at time 0, e is the natural logarithm, b is the slope and x is the time. 
| Quantitative RT-PCR (qRT-PCR)
Total RNA was isolated from snap-frozen kidney samples using NucleoSpin ® RNA Plus kit (Macherey-Nagel GmbH; Takara Bio USA).
RNA samples ( 
| Western immunoblotting
Kidney tissue and HK-2 cell samples were homogenized in ice-cold RIPA buffer. Proteins were separated by SDS-polyacrylamide gel (4%-20%) electrophoresis as we have previously described. 41 Immunoreactive proteins were visualized and documented using a gel documentation system (Bio-Rad, Hercules, CA, USA).
| Human proximal tubule epithelial cell line (HK-2)
The use of HK-2 cell line was approved, and experiments were per- 
| Data analysis
Statistical analysis was performed using the GraphPad Prism and The mean GFR in captisol-treated control mice was~1.5 mL/ min/g kidney weight which was similar to that in mice treated with DAPT alone ( Figure 3F ). Cisplatin reduced GFR in the mice by~51% ( Figure 3F ); an effect attenuated by DAPT ( Figure 3F ).
These findings suggest (a) DAPT alone does not alter renal function, (b) Notch signaling induction contributes to AKI elicited by cisplatin and (c) DAPT alleviates cisplatin-induced renal insufficiency in mice.
| DAPT protects against renal morphological changes induced by cisplatin
The kidney-to-body weight ratio in Captisol-and DAPT-treated mice was similar ( Figure 4A ). Cisplatin significantly increased the kidneyto-body weight ratio in the mice; an effect abrogated by DAPT (Figure 4A ). There were no noticeable histopathological changes in the group of mice treated with the vehicle (Captisol) and DAPT alone, where tubules and glomeruli were normal in appearance ( Figure 4B ).
Cisplatin caused tubular injury exemplified by overt necrosis and vacuolar degeneration which were attenuated by DAPT ( Figure 4B , C). These data indicate that DAPT preserves renal morphology in cisplatin-induced AKI. Cisplatin-induced increase in PI fluorescence intensity was reversed by DAPT ( Figure 5A,B) . Similarly, fast line-scanning of peritubular capillaries showed distorted blood flow indicated by the variable slope in cisplatin-treated mice compared with the constant slope in Captisol-, DAPT-and DAPT + cisplatin-treated mice ( Figure 5C ).
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Caspase 3 activity was elevated~2-fold in the whole kidneys of cisplatin-treated mice compared with the mice treated with Captisol and DAPT ( Figure 5D ). Cisplatin-induced caspase 3 activity was inhibited by DAPT ( Figure 5D ). Also, DAPT ameliorated cisplatin-induced upregulation of pro-apoptotic Bax and downregulation of anti-apoptotic Bcl-2 genes in the kidneys (Figure 6A,B) . Together, these findings signify that cisplatin-driven Notch signaling elicits renal cell death and peritubular vascular dysfunction. The Notch pathway regulates nephrogenesis. 12, 43 However, recent studies indicated that increased expression and activity of Notch components are associated with AKI and chronic kidney disease. 14, 15 The expression levels of Notch ligands, receptors and transcriptional targets were all increased in rodents subjected to renal ischemia-reperfusion.
44-46
The Notch pathway is also induced in animals and human with diabetes, kidney fibrosis and glomerulosclerosis. 14,15 Accordingly, suppression of Notch signaling by inhibiting proteolytic cleavage of Notch receptors alleviated acute and chronic kidney disease. 14, 15, 44, 47, 48 Data here signify that the basal protein expression level of N1ICD in mouse kidney is low.
Additionally, we did not detect alterations in basal renal function in mice treated with DAPT alone. These findings corroborate previous reports suggesting that basal Notch signaling is reduced or absent in healthy adult kidneys. 14, 15 Cisplatin increased Dll1 and N1ICD expression in mouse | 267
Our findings indicate that Dll1 stimulates N1ICD processing.
Given that the Notch pathway is regulated by a variety of signaling molecules, including five ligands, our data did not unequivocally determine that Dll1 induction was solely responsible for N1ICD
cleavage and renal injury in the mice. We show that cisplatin inversely altered dll1 and Jag1 expression in whole kidneys and cultured HK-2 cells. It is conceivable that cisplatin triggers compensatory expression and function of renal Dll1 and Jag1 as Notch ligands may respond to different cellular signals or stimulate distinct Notchdependent biological processes. 49, 50 Jag1 expression was increased in obstructed mouse kidneys and TGF-β1-treated renal cortical epithelial cells. 51 Dll1, but not Jag1, Jag2, Dll3 or Dll4 expression levels were increased in the kidneys of rats subjected to ischemia/ reperfusion. 46 A study has also reported that cadmium chloride stimulated N1ICD cleavage and cell death while reducing Jag1 expression in HK-2 cells. 52 Together, these studies suggest that alterations in Notch ligand expression and activity in the kidney may depend on the type of renal insult.
Notch signaling is induced in hematologic malignancies such as T-cell acute lymphoblastic leukemia and lymphoma, multiple myeloma and acute myelogenous leukemia as well as solid tumors. [53] [54] [55] On the other hand, Notch signaling exhibited tumor-suppressing activity in hepatocellular carcinoma, chronic myelomonocytic leukemia and head and neck squamous cell carcinoma. [53] [54] [55] Mechanisms of the protective effect of DAPT against cisplatininduced nephrotoxicity appears to include inhibition of caspasedependent and -independent cell death as cisplatin-induced necrosis, caspase 3 activity, increase in pro-apoptotic Bax and a compensatory decrease in anti-apoptotic Bcl-2 were all attenuated by DAPT. It is intriguing that DAPT inhibited cisplatin-induced cell death in the kidney but promoted cisplatin-induced cancer cytotoxicity. transmembrane proteins including the amyloid β precursor protein (AβPP) can be cleaved by the enzymes. 58, 59 However, AβPP intracellular domain has been shown to degrade N1ICD, thereby inhibiting Notch1 signaling. 60 Induction of both renal Dll1 and N1ICD by cisplatin and reversal of renal Notch1 cleavage by DAPT indicate that DAPT mitigates cisplatin-induced AKI by suppressing Notch signaling.
In conclusion, our data suggest that Dll1-mediated Notch1 signaling contributes to cisplatin-induced AKI. Pharmacological inhibition of the Notch signaling pathway preserved renal function and morphology in cisplatin-treated mice and viability in cisplatin-treated human proximal tubule cell line. Hence, inhibition of Notch signaling could be a potential therapeutic strategy to alleviate renal complications associated with cisplatin chemotherapy.
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